Qiagen (NYSE:QGEN) had its target price cut by equities researchers at Morgan Stanley from $39.00 to $37.00 in a report issued on Wednesday, Stock Target Advisor reports. The brokerage presently has an “overweight” rating on the stock. Morgan Stanley’s price objective would suggest a potential upside of 13.57% from the stock’s previous close.
Separately, DZ Bank reaffirmed a “neutral” rating on shares of Qiagen in a research report on Thursday, April 5th.
Qiagen stock opened at $32.58 on Wednesday. Qiagen has a 52-week low of $27.83 and a 52-week high of $36.34. The company has a quick ratio of 4.59, a current ratio of 5.07 and a debt-to-equity ratio of 0.69. The stock has a market cap of $7,312.62, a price-to-earnings ratio of 25.17, a PEG ratio of 1.98 and a beta of 1.02.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.